Sibutramine for weight gain attenuation during smoking cessation with varenicline

A pilot study

Research output: Contribution to journalArticle

3 Citations (Scopus)

Abstract

Introduction: Weight gain following tobacco abstinence is a significant barrier to cessation. Varenicline is the most effective medication for smoking cessation but does not prevent weight gain. Combining sibutramine and varenicline may facilitate smoking abstinence if weight gain is attenuated. Methods: Our aim was to assess the safety and efficacy of sibutramine for weight gain prevention among women quitting smoking with varenicline. Ten smokers enrolled in a pilot study of open-label sibutramine and varenicline for 12 weeks. Results: Participants rated themselves low on appearance evaluation, health evaluation, health orientation, and body-areas satisfaction. Ninety percent reported that they would return to smoking if they gained weight after stopping smoking. For the 6 subjects who met criteria for prolonged abstinence, weight change from baseline to Week 12 (11 weeks after the target quit date) was 0.2 ± 1.3 kg, and the 7-day point-prevalence smoking abstinence rate at Week 12 was 70% (95% CI 35%-93%). Discussion: Combination therapy with sibutramine and varenicline for weight gain prevention and smoking cessation as an intervention for smokers at risk for relapse to smoking because of weight gain may warrant further investigation.

Original languageEnglish (US)
Pages (from-to)1479-1484
Number of pages6
JournalNicotine and Tobacco Research
Volume11
Issue number12
DOIs
StatePublished - 2009

Fingerprint

sibutramine
Smoking Cessation
Weight Gain
Smoking
Weights and Measures
Health
Tobacco
Varenicline

ASJC Scopus subject areas

  • Public Health, Environmental and Occupational Health

Cite this

@article{708a14d43868438a9b73b07f5a1062c3,
title = "Sibutramine for weight gain attenuation during smoking cessation with varenicline: A pilot study",
abstract = "Introduction: Weight gain following tobacco abstinence is a significant barrier to cessation. Varenicline is the most effective medication for smoking cessation but does not prevent weight gain. Combining sibutramine and varenicline may facilitate smoking abstinence if weight gain is attenuated. Methods: Our aim was to assess the safety and efficacy of sibutramine for weight gain prevention among women quitting smoking with varenicline. Ten smokers enrolled in a pilot study of open-label sibutramine and varenicline for 12 weeks. Results: Participants rated themselves low on appearance evaluation, health evaluation, health orientation, and body-areas satisfaction. Ninety percent reported that they would return to smoking if they gained weight after stopping smoking. For the 6 subjects who met criteria for prolonged abstinence, weight change from baseline to Week 12 (11 weeks after the target quit date) was 0.2 ± 1.3 kg, and the 7-day point-prevalence smoking abstinence rate at Week 12 was 70{\%} (95{\%} CI 35{\%}-93{\%}). Discussion: Combination therapy with sibutramine and varenicline for weight gain prevention and smoking cessation as an intervention for smokers at risk for relapse to smoking because of weight gain may warrant further investigation.",
author = "Amit Sood and Ebbert, {Jon Owen} and Clark, {Matthew M} and Croghan, {Ivana T} and Schroeder, {Darrell R.} and Hays, {James Taylor}",
year = "2009",
doi = "10.1093/ntr/ntp162",
language = "English (US)",
volume = "11",
pages = "1479--1484",
journal = "Nicotine and Tobacco Research",
issn = "1462-2203",
publisher = "Oxford University Press",
number = "12",

}

TY - JOUR

T1 - Sibutramine for weight gain attenuation during smoking cessation with varenicline

T2 - A pilot study

AU - Sood, Amit

AU - Ebbert, Jon Owen

AU - Clark, Matthew M

AU - Croghan, Ivana T

AU - Schroeder, Darrell R.

AU - Hays, James Taylor

PY - 2009

Y1 - 2009

N2 - Introduction: Weight gain following tobacco abstinence is a significant barrier to cessation. Varenicline is the most effective medication for smoking cessation but does not prevent weight gain. Combining sibutramine and varenicline may facilitate smoking abstinence if weight gain is attenuated. Methods: Our aim was to assess the safety and efficacy of sibutramine for weight gain prevention among women quitting smoking with varenicline. Ten smokers enrolled in a pilot study of open-label sibutramine and varenicline for 12 weeks. Results: Participants rated themselves low on appearance evaluation, health evaluation, health orientation, and body-areas satisfaction. Ninety percent reported that they would return to smoking if they gained weight after stopping smoking. For the 6 subjects who met criteria for prolonged abstinence, weight change from baseline to Week 12 (11 weeks after the target quit date) was 0.2 ± 1.3 kg, and the 7-day point-prevalence smoking abstinence rate at Week 12 was 70% (95% CI 35%-93%). Discussion: Combination therapy with sibutramine and varenicline for weight gain prevention and smoking cessation as an intervention for smokers at risk for relapse to smoking because of weight gain may warrant further investigation.

AB - Introduction: Weight gain following tobacco abstinence is a significant barrier to cessation. Varenicline is the most effective medication for smoking cessation but does not prevent weight gain. Combining sibutramine and varenicline may facilitate smoking abstinence if weight gain is attenuated. Methods: Our aim was to assess the safety and efficacy of sibutramine for weight gain prevention among women quitting smoking with varenicline. Ten smokers enrolled in a pilot study of open-label sibutramine and varenicline for 12 weeks. Results: Participants rated themselves low on appearance evaluation, health evaluation, health orientation, and body-areas satisfaction. Ninety percent reported that they would return to smoking if they gained weight after stopping smoking. For the 6 subjects who met criteria for prolonged abstinence, weight change from baseline to Week 12 (11 weeks after the target quit date) was 0.2 ± 1.3 kg, and the 7-day point-prevalence smoking abstinence rate at Week 12 was 70% (95% CI 35%-93%). Discussion: Combination therapy with sibutramine and varenicline for weight gain prevention and smoking cessation as an intervention for smokers at risk for relapse to smoking because of weight gain may warrant further investigation.

UR - http://www.scopus.com/inward/record.url?scp=70849135779&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=70849135779&partnerID=8YFLogxK

U2 - 10.1093/ntr/ntp162

DO - 10.1093/ntr/ntp162

M3 - Article

VL - 11

SP - 1479

EP - 1484

JO - Nicotine and Tobacco Research

JF - Nicotine and Tobacco Research

SN - 1462-2203

IS - 12

ER -